BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

...of new drugs in dermatology caused in part by large pharmas like Allergan plc and Valeant Pharmaceuticals International Inc....
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...a $650 million follow-on. Were it not for 2017’s $6.5 billion in notes deals by Valeant Pharmaceuticals International Inc....
BioCentury | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

...Next steps could include investigating the mechanism by which brain lymphatic vessels contribute to MS. Valeant Pharmaceuticals International Inc....
BioCentury | Sep 14, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of...
BioCentury | Sep 13, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of...
BioCentury | Aug 3, 2018
Finance

Earnings on deck

...least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant Pharmaceuticals International Inc....
BioCentury | Jul 13, 2018
Finance

Pause for politics

...period was aided by $3.8 billion in M&A-related equity raises by Endo International plc and Valeant Pharmaceuticals International Inc....
...Ltd. (HKSE:1833), Shanghai, China Shenogen Pharma Group Ltd. Beijing, China State Drug Administration, Beijing, China Valeant Pharmaceuticals International Inc....
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...a complete response letter for Furoscix (scFurosemide) to treat edema in patients with heart failure Valeant Pharmaceuticals International Inc....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...acid (ETC-1002) / ezetimibe ASCVD Top-line Ph III data August EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) / Valeant Pharmaceuticals International Inc....
...NASDAQ:URGN) MitoGel (UGN-101) Low-grade upper tract urothelial carcinoma (UTUC) Top-line Ph III OLYMPUS data 2H18 Valeant Pharmaceuticals International Inc....
BioCentury | Jun 22, 2018
Clinical News

Valeant receives complete response letter for psoriasis candidate

...The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it received a complete response letter from...
...Duobrii is a topical formulation of halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug. Valeant Pharmaceuticals International Inc....
Items per page:
1 - 10 of 889
BioCentury | Jun 21, 2019
Emerging Company Profile

Arcutis: Reformulating dermatology

...of new drugs in dermatology caused in part by large pharmas like Allergan plc and Valeant Pharmaceuticals International Inc....
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...a $650 million follow-on. Were it not for 2017’s $6.5 billion in notes deals by Valeant Pharmaceuticals International Inc....
BioCentury | Sep 20, 2018
Distillery Therapeutics

Autoimmune disease

...Next steps could include investigating the mechanism by which brain lymphatic vessels contribute to MS. Valeant Pharmaceuticals International Inc....
BioCentury | Sep 14, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of...
BioCentury | Sep 13, 2018
Financial News

Xenon further strengthens balance sheet with $63M follow-on

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) raised $63 million through the sale of 4.5 million shares at $14 in a follow-on underwritten by Jefferies and Stifel. The price is a 2% discount to Xenon's closing price of...
BioCentury | Aug 3, 2018
Finance

Earnings on deck

...least 8 profitable biotechs and pharmas are slated to report earnings this week. (A) Formerly Valeant Pharmaceuticals International Inc....
BioCentury | Jul 13, 2018
Finance

Pause for politics

...period was aided by $3.8 billion in M&A-related equity raises by Endo International plc and Valeant Pharmaceuticals International Inc....
...Ltd. (HKSE:1833), Shanghai, China Shenogen Pharma Group Ltd. Beijing, China State Drug Administration, Beijing, China Valeant Pharmaceuticals International Inc....
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...a complete response letter for Furoscix (scFurosemide) to treat edema in patients with heart failure Valeant Pharmaceuticals International Inc....
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...acid (ETC-1002) / ezetimibe ASCVD Top-line Ph III data August EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) / Valeant Pharmaceuticals International Inc....
...NASDAQ:URGN) MitoGel (UGN-101) Low-grade upper tract urothelial carcinoma (UTUC) Top-line Ph III OLYMPUS data 2H18 Valeant Pharmaceuticals International Inc....
BioCentury | Jun 22, 2018
Clinical News

Valeant receives complete response letter for psoriasis candidate

...The Ortho Dermatologics unit of Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it received a complete response letter from...
...Duobrii is a topical formulation of halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug. Valeant Pharmaceuticals International Inc....
Items per page:
1 - 10 of 889